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Abstract Eosinophilic granulomatosis with polyangiitis
(EGPA) is a rare, autoimmune small and medium vessel
vasculitis. EGPA is accompanied by asthma and involves
mainly the blood vessels of the lungs, gastrointestinal sys-
tem, and peripheral nerves; however, the skin, kidneys, and
heart may be also affected. To investigate if patients with
EGPA experience reduced health-related quality of life
(HRQOL), and the effect of this parameter on their own
perception of future health outlook. Twenty-six EGPA
patients are in disease remission and completed a custom-
designed questionnaire and the Medical Outcomes Study
Short Form 36 (SF-36). Using the RAND method, eight
HRQOL dimensions were calculated: general health, phys-
ical functioning, emotional role limitations, physical role
limitations, social functioning, mental health, bodily pain,
and vitality. Using norm-based scores, the HRQOL of
patients was compared with that of the general population.
EGPA patients had decreased HRQOL across all eight
dimensions of the SF-36. Patients with higher mental com-
ponent score felt more positive about their future health,
while patients with low physical component score were
likely not to feel negatively about their future health. Also,
36 % of older patients (>50 years) had a positive outlook
compared to 47 % of younger patients (<50 years) and
patients with a longer disease course were much less likely
to have a positive outlook (30 % positive) than those with a
shorter course (50 % positive). Although not statistically
significant, these correlations warrant further investigation
with a larger patient population. Despite being in disease
remission, EGPA patients had decreased quality of life,
which in turn influenced their perception of their future
health outlook.
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Introduction
Eosinophilic granulomatosis with polyangiitis (EGPA), pre-
viously known as Churg–Strauss syndrome, is a non-
inheritable and nontransmissible disease affecting medium
and small vessels. It is an autoimmune vasculitis leading to
tissue necrosis with eosinophilia and eosinophil tissue infil-
tration [1]. EGPA is accompanied by asthma and involves
mainly the blood vessels of the lungs, gastrointestinal sys-
tem, and peripheral nerves; however, other organs such as
skin, kidneys, and most notably the heart may also be
affected [2, 3]. Over the years, the prognosis for EGPA
patients has improved tremendously. After the introduction
of corticosteroids into therapy, 5-year mortality rates have
decreased to 13.9 % from previously reported 3-month rates
of approximately 50 % [4, 5]. It can be safely said that, over
the last decade, EGPA has been reduced to a chronic relaps-
ing disease usually requiring indefinite medication and pe-
riodic follow-up. The question thus arises whether this
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improvement has had a proportionally positive impact on
the quality of life in these patients. Additionally, the under-
standing of the term “health” has also changed dramatically
during this time and—unsurprisingly—patients’ expecta-
tions have evolved correspondingly. In fact, many of them
expect not only to be physically and emotionally healthy but
to also enjoy a quality of life similar to that of people
unaffected by disease.
Quality of life is defined as an individual’s perception of
their position in life in the context of the culture and value
systems in which they live and in relation to their goals,
expectations, standards, and concerns [6]. Measurement of
such a relative parameter is challenging. Standardized meth-
ods such as the health-related quality of life (HRQOL) Short
Form 36 (SF-36) have become a useful tool in measuring
the quality of life of distinct patient populations and com-
paring it to healthy populations at one moment in time. It is
also used to monitor the impact of novel treatments methods
on the quality of life over a prolonged period of time [7].
The additional advantage of using such tools is that
they provide a uniform platform which facilitates the
comparison of quality of life measurements across sim-
ilar types of diseases [8].
Although SF-36 has been used in patients with many
auto-immune diseases such as granulomatosis with polyan-
gitiis disease (GPA, Wegener’s granulomatosis) [9], system-
ic lupus erythematosus [10], newly diagnosed antineutrophil
cytoplasmic antibody (ANCA)-associated vasculitis [8],
there has been no study using this method that focuses
solely on patients with eosinophilic granulomatosis with
polyangiitis. EGPA patients suffer from a unique set of
symptoms that affect their daily lives in ways different from
other vasculitic diseases. This is partially due to the consid-
erable burden that asthma places on patient’s daily living
activities, especially before a diagnosis is made [11].
Another question that has not been addressed is how
patients’ feel about their perceived future health outlook,
an important yet rarely considered outcome measure [12],
and what factors influence this perception.
These reasons prompted the investigation of whether cur-
rent quality of life in EGPA patients exerts any influence on
their future health outlook. Several other significant factors
such as gender, employment, and duration of disease were
also screened for correlation with future health outlook.
Patients and methods
Medical records from the Outpatient Allergy and Immunology
Clinic of the Jagiellonian University Hospital in Cracow,
Poland were searched to identify patients with EGPA. The
diagnosis was verified before enrollment in all patients includ-
ed in this study. As no diagnostic criteria are available for
EGPA, the American College of Rheumatology (ACR) classi-
fication criteria were used [13]. They are the most widely
accepted criteria in this condition. They distinguish six key
features of the disease, among them: asthma, peripheral blood
eosinophilia of >10 %, mono- or polyneuropathy, paranasal
sinus abnormality, eosinophilic accumulation in tissues con-
firmed by a biopsy, and migratory infiltrates in lungs. At least
four of the criteria listed above had to be confirmed in order to
validate the diagnosis. A custom questionnaire regarding cur-
rent symptoms, current medication regimen, and employment
history, Short Form 36 Health Survey (QualityMetrics v. 2) as
well as future health outlook were included in the survey
package. The Short Form 36 Health Survey, a standardized
questionnaire, is used to compile two key parameters: a mental
component score (MCS) and a physical component score
(PCS). An absolute score (0–100) was obtained for each
parameter. Using the RAND method, a total of eight
HRQOL dimensions were measured: general health (GH),
physical functioning (PF), emotional role limitations (RE),
physical role limitations (RP), social functioning (SF), mental
health (MH), bodily pain (BP), and vitality (VT). A score of 50
was judged to be equivalent to the general population while
scores above or below this threshold indicated that a
corresponding difference from the normal population was
present. Using norm-based scores, we compared the HRQOL
of patients with a sample from a general population. Patients
were also asked to assess how they currently perceive their
personal future health outlook as one of three options: positive,
negative, or unchanged. The available medical documentation
and survey data were used to analyze the disease course and
evaluate its activity by the Birmingham Vasculitis Activity
Score (BVAS) score (BVAS v.3; range, 0–56 patients. avail-
able at http://www.vasculitis.org/disease.htm) [14]. Patients
with BVAS <2 were assumed to be in disease remission and
included to the study. The survey packages were mailed to
personal home addresses with return postage paid. All subjects
gave informed consent to participate prior to inclusion in the
study. Patients answered the survey and mailed it back to the
hospital. The study protocol complied with the Helsinki
Declaration and was approved by the Jagiellonian University
Ethics Committee.
Statistical analysis was performed using Statistica
(Statsoft, v10.0) software. Descriptive statistical analyses
were performed for all. Ninety-five percent confidence
intervals were also calculated on the basis of the Poisson
distribution. The distributions of the response variables were
checked for normality and transformations were performed
as appropriate. When the pattern of the results observed
using the transformed scores was similar to the results
obtained from the raw data analysis, the raw data analysis
is presented; if different, we report the results obtained using
the transformed scores. Nonparametric tests were used as
appropriate where the normality assumptions could not be
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met. The data were analyzed using Mann–Whitney U tests
and Fisher’s test. p values less than 0.05 were considered as
statistically significant.
Results
A hospital database search identified 30 patients diagnosed
with EGPA between July 1998 and December 2011. Each
case was confirmed according to the ACR criteria for diag-
nosis of eosinophilic granulomatosis with polyangiitis and
all of these patients were treated by a single medical team
throughout the duration of their disease. From among the 30
patients who received survey packages, 26 replied and one
was reported to be deceased. All of the respondents were
included in this study. There were 26 patients (9 males and
17 females) with a mean age of 46±13 years. The mean
disease duration was 63±42 months. All patients were con-
firmed to be currently in complete remission with a score of
<2 on the BVAS. The baseline characteristics of the study
population are show in Table 1. Additionally, a case-by-case
review of medical records for confirmation of ACR criteria
revealed asthma in 26 patients (100 %), sinusitis in 22
patients (85 %), eosinophilia in peripheral blood in 26
patients (100 %), mono or poly-neuropathy in 16 (62 %)
and pulmonary eosinophilic infiltration in 20 (77 %). A
tissue biopsy was performed in 13 cases (50 %); all results
confirmed presence of vasculitis. The employment history
of the study population is presented in Table 2. The majority
of patients were employed at diagnosis (n=18, 69 %), but at
time of the study only 50 % (n=13) were employed (p=NS).
Among those working at diagnosis, one working patient (n=
1, 100 %) changed jobs during the course of their disease,
and did so because of EGPA. Among the unemployed, all
three patients who were unemployed before diagnosis found
new jobs despite developing EGPA and were working at the
time of study. However, two of them were not able to work
in their field due to EGPA and one of them was not affected
by this diagnosis when returning to work (data not shown).
Additionally, seven patients who previously worked became
pensioners, and all seven (100 %) of them did so because of
the impact of EGPA on their capacity to work. One working
patient at time of diagnosis retired but this was not due to
EGPA. The overall clinical picture of the study population
throughout the course of their disease is presented in
Table 3. The majority of subjects complained of sinus
(85 %) and dyspnea (85 %) at diagnosis but were bothered
mainly by sinus (54 %) and neuropathy (35 %) symptoms at
the time of study.
Overall, the results of the SF-36 survey pictured by the
tracings in Fig. 1, revealed patients with EGPA had lower
quality of life parameters across all eight dimensions when
compared with a normal population. Unemployment was
associated with lower HRQOL (Fig. 1b). Only the VT
dimension had a score that was almost identical to the
normal population (48.8 vs. 50). Next, Table 4 shows the
SF-36 survey results after patients were grouped into three
separate categories according to their perceived personal
future health outlook (available options: positive, un-
changed, and negative). This breakdown revealed reverse
trends by the two major component scores (MCS and PCS)
of the SF-36 instrument. The MCS showed a correlation
with a positive health outlook highlighted by an increase
from 38.4 (below the population norm) in patients with a
negative outlook to 50.4 (equal to population norm) in
patients with a positive outlook. In contrast, the PCS de-
crease showed a negative trend with scores falling from 45.5
(below the population norm) in patients with negative future
outlook to 41 (below the population norm) in patients with a
positive outlook. The PF score decrease from 51.3 (equal to
population norm) in patients with a negative outlook to 41
(below the population norm) in patients with positive out-
look was found to be the only statistically significant differ-
ence (p=0.01).
The breakdown of patients according to perceived future
health outlook is presented in Table 5. Overall, there were 11
patients who had a positive outlook, 9 thought it would
remain unchanged and 6 had a negative outlook. Global
HRQOL was lower in patients with a negative outlook
(Fig. 1b). There were no significant differences between males
(n=4, 44 % positive) and females (n=7, 41 % positive). Their
current work situation also did not seem to influence their
outlook with employed (46 % positive) and unemployed
(38 % positive) having similar opinions regarding their future
disease course. Two characteristics associated with a positive
health outlookwere young age (<50 years) and shorter disease
course. Approximately 36 % of older patients (>50 years) had
positive outlook compared to 47 % of younger patients
Table 1 Baseline characteristics of study population
Total patients n=26
Females, n (%) 17 (65 %)
Males, n (%) 9 (35 %)
Median age at diagnosis (years±SD, range) 41±14 (15–67)
Females 39±10 (19–60)
Males 45±19 (15–67)
Median age at study (years±SD, range) 46±13 (18–69)
Females 44±10 (22–62)
Males 51±16 (18–69)
Median duration of disease at survey
(months±SD, range)
63±42 (6–180)
Females 57±32 (6–120)
Males 75±57 (12–180)
Presented as absolute numbers and percentage of total. Age presented
in years±SD with range
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(<50 years). Themost significant differentiating factor was the
length of duration of disease where patients with a longer
course of disease (30 % positive) were much less likely to
have a positive outlook than those with shorter ones (50 %
positive). These correlations were, however, not statistically
significant.
Discussion
The aim of this study was to evaluate the current quality of
life in EGPA patients and how this factor impacts their
future health outlook. The patients overall quality of life
was lower than the normal population across all dimensions
of the SF-36 survey. This is the first study to directly
investigate HRQOL in eosinophilic granulomatosis with
polyangiitis patients via a standardized method (SF-36) that
yields results which allow for direct comparison with other
related diseases. Although EGPA patients have been includ-
ed as part of larger studies [8], they made up an insignificant
proportion of total study subjects and results may not accu-
rately reflect the quality of life of these patients. When
compared to other vasculitic diseases, these results show
similar patterns to previously reported studies of diseases
such as GPA [9] which revealed a similarly decreased level
quality of life, most noticeably in patients who were
Table 2 Employment profile of
study population at diagnosis
and time of study
At time of diagnosis At study time Changes due to EGPA
Employed Median
age
41±10 (26–57) Median age 42±8 (34–57)
Male 13 Male 9
Females 5 Females 4
Total 18 Total 13 Patients who changed jobs because
of EGPA: 2 (100 %) n (% of total
patients who changed jobs)
Unemployed Median
age
34±9 (23–41) Median age n/a
Male 2 Male 0
Females 1 Females 0
Total 3 Total 0 Patients who lost their jobs because
of EGPA: 0 (0 %) n (% of total
new unemployed)
Retired 3 4 Newly retired because of EGPA: 1
(100 %) n (% of newly retired)
Pensioners 0 7 New pensioner because of EGPA: 7
(100 %) n (% of new pensioners)
Students 2 2 New students: 0 (0 %)
n (% of new students)
Table 3 Symptoms history and
characteristics of study
population
Included were self-reported
symptoms reported on custom
questionnaire. Results include
absolute number of patients and
percentage of total (n=26).
Empty fields denote that no
patients reporting corresponding
symptom. Patients were able to
name more than one symptom in
first and second column but only
one in third column
Symptoms at
diagnosis
Dominant symptoms
(over last 12 months)
Worst symptoms since
diagnosis (one symptom)
Cough, n (%) 20 (77 %) 5 (19 %) 3 (11.5 %)
Dyspnea, n (%) 22 (85 %) 7 (27 %) 11 (42 %)
Fever, n (%) 18 (69 %) 0 –
Malaise, n (%) 25 (96 %) 1 (4 %) 3 (11.5 %)
Post-nasal drip, n (%) 4 (15 %) 4 (15 %) –
Sinusitis, n (%) 22 (85 %) 14 (54 %) 1 (4 %)
Hay fever, n (%) 22 (85 %) 3 (12 %) –
Paranasal sinus abnormality, n (%) 8 (31 %) 2 (8 %) –
Neuropathy, n (%) 16 (62 %) 9 (35 %) 5 (19 %)
Weight loss, n (%) 12 (46 %) 0 –
Skin changes, n (%) 11 (42 %) 0 –
Pain, n (%) 10 (38 %) 5 (19 %) 2 (8 %)
Sight/hearing/smell disorders, n (%) 1 (4 %) 2 (8 %) 1 (4 %)
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unemployed [15, 16]. A large study of ANCA-associated
vasculitides found significantly decreased HRQOL at diag-
nosis most notably linked with neurologic involvement [8].
Finally, a Japanese study confirmed that even though quality
of life improved over the 18 months the patients were
included in a clinical trial, the SF-36 results were still below
the population norm [17]. Taken together, the level of
HRQOL decrease across the various vasculitic diseases,
including the results of the present study, is similar in nature
and in magnitude.
A major complaint among EGPA patients are symptoms
of dyspnea and cough which are typically asthma related. In
comparison, a large (n=586) and very recent analysis of the
Epidemiological Study on the Genetics and Environment of
Asthma cohort via SF-36 analysis revealed that HRQOL in
well-controlled asthma patients remains relatively unaffect-
ed by their condition, where patients with uncontrolled
asthma are the only ones who have a significant difference
in HRQOL at time of study when compared to patients with
well-controlled asthma [18]. These results are similar to
those obtained in this study which shows that asthma symp-
toms do not significantly influence the HRQOL. In fact, we
performed a multivariable analysis which revealed that the
only significant determinant of HRQOL is peripheral ner-
vous system involvement, confirming previous results de-
scribed by Walsh et al. [8]. Other affected organs systems
like the cardiovascular system, respiratory system, sinuses,
kidneys, as well as long-term immunosuppression did not
PCS - physical component summary; MCS - mental component summary; GH - general health; 
PF - phisicial functioning; RP -role physical; BP - bodily pain; VT vitality; SF - social 
functioning; RE - role emotional; MH mental health.
a bFig. 1 Spydergrams of SF-36
results of EGPA patients com-
pared to the general population
grouped according to perceived
health outlook (a) and employ-
ment status (b). PCS physical
component summary, MCS
mental component summary,
GH general health, PF physical
functioning, RP role physical,
BP bodily pain, VT vitality, SF
social functioning, RE role
emotional, MH mental health
Table 4 Indexed scores of the SF-36 survey’s eight dimensions grouped according to patient’s future health outlook
Future health outlook
Negative (n=6) p Unchanged (n=9) p Positive (n=11) p
MCS (mental component score) 38.4±14.4 0.17 45.6±9.2 0.64 50.4±7.4 0.12
PCS (physical component score) 45.5±5.6 0.73 46.5±8.9 0.59 41.0±10.4 0.4
GH (general health) 37.3±7.8 0.39 40.5±10.6 0.97 41.7±7.3 0.55
PF (physical functioning) 51.3±5 0.23 49.7±8.7 0.10 41.0±8.7 0.01
RP (role physical) 43.1±8.5 0.97 45.2±11 0.38 40.4±8.5 0.38
BP (bodily pain) 39.4±9.4 0.29 47.3±13 0.87 49.3±12.3 0.92
VT (vitality) 46.7±13.7 0.9 49.3±9.3 0.81 47.6±9.2 0.71
SF (social functioning) 43.6±17.1 0.9 42.9±10.2 0.61 45.1±13.8 0.71
RE (role emotional) 44.9±14.9 0.75 48.4±13.5 0.68 48.8±7.9 0.89
MH (mental health) 41.7±12.5 0.44 44.5±9 0.53 48.5±6.7 0.2
Data expressed as mean value±SD
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impact the HRQOL at time of study. Although asthma and
its symptoms were not associated with a significant influ-
ence on the HRQOL at time of study in our analysis, these
symptoms were mentioned as the most bothersome through-
out the entire course of the disease (Table 3). Previous work
by our group describing the course of asthma in patients
with EGPA revealed an atypical course of this disease [11].
This study found that although EGPA patients suffer from
severe asthma at the moment of diagnosis; these symptoms
gradually subside over time and remain well controlled.
Also, employment status has been confirmed as an im-
portant determinant of HRQOL in past studies. Interestingly,
in our study, employment did not influence either the current
HRQOL or the future health outlook in a statistically sig-
nificant manner. Other findings include a large proportion of
the study population (7/26) requiring to apply for a pension.
This did not translate into a statistically significant differ-
ence in HRQOL measures.
Notably, a novel contribution of this study is the exami-
nation of patients’ perceived future health outlook as an
independent factor resulting from current HRQOL. The
results obtained in this study suggest that the MCS is the
most reliable predictor in reference to patients’ perception of
their own health. Patients with higher MCS scores felt more
optimistic about the future while patients with low PCS
were likely not to be more pessimistic about their future
health. Thus, it seems fair to conclude that MCS carries
substantially more weight in shaping patients’ perceived
future health outlook. In other words, patients who feel most
positively about their future health outlook, currently exhibit
the highest quality of life from a psychological point of
view. This result is surprising and should serve to alert
physicians that, paradoxically, patients with a positive frame
of mind may actually be in a worse physical health state than
their counterparts who seem more pessimistic about their
future health. The finding that patients with the lowest PCS
scores remained positive about their future outlook may be
explained by the fact that, at diagnosis, the disease mani-
fested itself in its most severe form. Hence, these patients
have witnessed a significant improvement over the years
and remain hopeful of further improvements to come. In
contrast, patients who may have had lighter forms of the
disease and whose quality of life remained initially unaf-
fected could account for the fact that these patients have a
bleak outlook going forward. Arguably, these conclusions
could only be considered accurate once a statistically sig-
nificant correlation is achieved by working with a larger
sample group. Limitations of this analysis are mainly due
to the small number of patients included in this study (n=
26) as EGPA is a very rare disease. This makes the statistical
correlation analysis difficult. Additionally, a baseline SF-36
result obtained at the time of diagnosis could have been
useful to identify expectation bias. Establishing this baseline
may distinguish if patients who currently suffer from the
lowest physical well-being yet perceive their future health
positively do so because they are the ones which have
improved the most over the years. Their improvements
could skew their future outlook as they may be looking
forward to similar improvements in the future. In the same
vein, a follow-up questionnaire at 1 year would likely con-
firm certain trends and extract new trends which have gone
unnoticed within the limited amount of data gathered.
Finally, an obvious amelioration of the validity of these
results would be an expansion of the sample size to include
more patients and gain increased statistical power.
Conclusion
Patients with EGPA had decreased HRQOL across all eight
dimensions of the SF-36. Patients with higher MCS felt
more positive about their future health, while patients with
low PCS were likely not to feel negatively about their future
health. Despite being in disease remission, patients with
EGPA had decreased quality of life, which in turn influ-
enced their perception of their future health outlook. A
larger study population with would be required to confirm
these findings in a statistically significant manner.
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Table 5 Characteristics of patient subgroups categorized according to
differences in perception of future health outlook
Future health outlook
Negative
(n=6)
Unchanged
(n=9)
Positive
(n=11)
Gender
Male (n=9) 2 (22 %) 3 (33 %) 4 (44 %)
Female (n=17) 4 (24 %) 6 (35 %) 7 (41 %)
Age (current)
<50 years (n=15) 2 (13 %) 6 (40 %) 7 (47 %)
>50 years (n=11) 4 (36 %) 3 (27 %) 4 (36 %)
Duration of disease
<66 months (n=16) 2 (12.5 %) 6 (37.5 %) 8 (50 %)
>66 months (n=10) 4 (40 %) 3 (30 %) 3 (30 %)
Employment
Employed (n=13) 2 (15 %) 5 (38 %) 6 (46 %)
Unemployed (n=13) 4 (31 %) 4 (31 %) 5 (38 %)
Results presented as absolute number of patients and percentage of
each category n (%)
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